Pain-Relieving Effects of mTOR Inhibitor in the Anterior Cingulate Cortex of Neuropathic Rats
- 690 Downloads
The anterior cingulate cortex (ACC) is a well-known brain area that is associated with pain perception. Previous studies reported that the ACC has a specific role in the emotional processing of pain. Chronic pain is characterized by long-term potentiation that is induced in pain pathways and contributes to hyperalgesia caused by peripheral nerve injury. The mammalian target of rapamycin (mTOR) signaling, which is involved in synaptic protein synthesis, could be a key factor controlling long-term potentiation in neuropathic pain conditions. Until now, there have been no reports that studied the role of mTOR signaling in the ACC involved in neuropathic pain. Therefore, this study was conducted to determine the relationship of mTOR signaling in the ACC and neuropathic pain. Male Sprague-Dawley rats were subjected to cannula implantation and nerve injury under pentobarbital anesthesia. Microinjection with rapamycin into the ACC was conducted under isoflurane anesthesia on postoperative day (POD) 7. A behavioral test was performed to evaluate mechanical allodynia, and optical imaging was conducted to observe the neuronal responses of the ACC to peripheral stimulation. Inhibition of mTOR by rapamycin reduced mechanical allodynia, down-regulated mTOR signaling in the ACC, and diminished the expressions of synaptic proteins which are involved in excitatory signaling, thereby reducing neuropathic pain-induced synaptic plasticity. These results suggest that inhibiting mTOR activity by rapamycin in the ACC could serve as a new strategy for treating or managing neuropathic pain before it develops into chronic pain.
KeywordsNeuropathic pain Anterior cingulate cortex mTOR Rapamycin Synaptic plasticity
Neuropathic pain is induced by various causes, including tissue or nerve damage, and is characterized by symptoms of spontaneous pain, allodynia, and hyperalgesia . Currently, many therapies such as antidepressants and antiepileptics are used to treat neuropathic pain, but these medications have side effects and are not always effective [2, 3, 4]. Thus, the management of neuropathic pain remains difficult. In the brain, cortical areas that process information related to pain are known as the “pain matrix,” which includes the anterior cingulate cortex (ACC), insular cortex (IC), thalamus, somatosensory cortex, and prefrontal cortex [1, 4, 5]. Among these regions, the ACC is the main area associated with pain perception , and accumulating evidence implicates the involvement of the ACC in the emotion processing of pain [7, 8].
Long-term potentiation (LTP) induced by repeated abnormal sensory signaling after peripheral nerve injury is a primary feature of chronic pain in the central nervous system, and the reinforcement of synaptic transmission is a core cellular mechanism of chronic pain . Such long-term synaptic plasticity or central sensitization in the spinal cord and cortical areas is known to contribute to chronic pain . In addition, changes in synaptic plasticity in the ACC are believed to be essential for the development and maintenance of chronic pain . For instance, a brain imaging study found increased ACC neuronal activity in persistent pain conditions , and animal behavior studies employing acute and chronic pain models showed that the development of LTP increases the number of pre- and post-synaptic AMPA and NMDA receptors in the ACC and that drugs that inhibit ACC activity exert analgesic effects . Therefore, these studies suggest that the ACC plays a vital role in processing pain-related information and in behavioral responses to various stimuli including noxious stimuli, inflammation, or nerve injury in humans and animals. In addition, a study utilizing a peripheral amputation model as well as an electrophysiological study reveals that excitatory transmission in the ACC is strengthened after peripheral nerve injury [13, 14]. In a rodent model of neuropathic pain, the development of allodynia is associated with synaptic potentiation in the ACC 1–2 weeks after nerve injury . This finding suggests that neuropathic pain is associated with mechanisms underlying the development of LTP in the ACC. In addition, nerve damage could induce long-term enhancement of synaptic transmission in the ACC, which would not only increase the release of neurotransmitters from presynaptic terminals but also increase the number of postsynaptic receptors. Preventing, eliminating, or reducing enhancement of excitatory transmission could be applied as a new therapeutic method for suppressing chronic pain. Previous studies show that neurons in the ACC respond to noxious stimuli  and that lesioning the ACC significantly reduces acute and neuropathic pain responses . However, inhibition of pain transmission does not prevent chronic pain-related synaptic strengthening, and drugs that suppress synaptic potentiation do not affect acute or physiological pain . Therefore, it is necessary to identify new therapeutic targets for controlling chronic pain by investigating the induction and formation mechanisms of pain-related LTP. LTP in chronic pain can be classified into early LTP maintained by existing proteins and late LTP (L-LTP) maintained through protein synthesis [18, 19]. In particular, L-LTP contributes to long-term changes in the cortical circuit due to synaptic protein synthesis induced by peripheral nerve injury. Thus, the regulation of protein synthesis may be an avenue for controlling LTP, and LTP maintenance and formation could be regulated by modulating mammalian target of rapamycin (mTOR), which is involved in synaptic protein synthesis.
mTOR is a serine-threonine protein kinase that plays a critical role in cell proliferation and differentiation in the nervous system . Activation of mTOR can be controlled through various stimuli (e.g., neurotransmitters, growth factors, cytokines, oxygen, and amino acids) . Activation of mTOR affects transcription of mRNA in a variety of physiological and pathologic pain states, including inflammatory and cancer pain [22, 23, 24, 25, 26], by phosphorylating downstream factors such as eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and p70 ribosomal S6 protein kinase (p70S6K) and is reported to be involved in signal transduction through regulation of protein synthesis . mTOR can also regulate cell growth, differentiation, and synaptic plasticity by activating synaptic protein synthesis . Thus, as LTP is maintained through synaptic protein synthesis , the modulation of synaptic protein synthesis through the regulation of mTOR activation may play an important role in LTP changes. Rapamycin, an mTOR inhibitor, has been used as an anticancer and immunosuppressive agent in the clinical treatment and has relatively few side effects compared with other drugs [26, 28]. Recent studies suggest that rapamycin, which regulates mTOR and its downstream effectors, could diminish chronic inflammatory, neuropathic, and cancer pain. Studies also report that mTOR activity is altered in a wide range of pathological states, such as cancer, cardiovascular diseases, and neurodegenerative disorders [26, 29, 30]. Pain behaviors (e.g., mechanical hypersensitivity) are reduced when rapamycin is intrathecally injected into hyperalgesia or inflammatory pain animal models or locally administrated in neuropathic pain animal models [22, 23, 24]. The inhibition of mTOR by treatment with the CCI-779, as confirmed by the decreased expression of downstream signaling molecules in the spinal cord and dorsal roots in a spared nerve injury animal model, exerts a pain-relieving effect . Previous studies report that mRNA translation and local protein synthesis are regulated by inhibiting mTOR activation in several pain models [32, 33]. In addition, our laboratory found that rapamycin reduces the expression of downstream signaling molecules and synaptic proteins in the IC . These previous studies strongly suggest that mTOR plays an important role in the modulation of long-term neuronal plasticity by preventing the establishment of LTP. So far, the mTOR pathway has been extensively studied in relation to cancer and described at the spinal cord level in relation to inflammatory and neuropathic pain, but only a few studies have been performed at the brain level. Moreover, there were no studies that have reported pain relief by controlling mTOR in the ACC of neuropathic pain models until now. It is necessary to conduct further studies at the brain level because the mTOR signaling pathway plays an important role in the neuronal plasticity involved in pain processing, such as the development of chronic pain. Therefore, the purpose of the present study was to investigate the association between pain caused by nerve injury and the mTOR signaling pathway in the ACC and to test the pain-relieving effect of rapamycin administration.
Materials and Methods
Adult male Sprague-Dawley rats that weigh 250–280 g (Harlan, Koatec, Pyeongtaek, Korea) were used in the present study. All animals were maintained under a 12-h light/dark cycle with free access to food and water throughout the study and were allowed to acclimate to the colony room for 7 days after arrival. All experimental protocols were in compliance with the National Institutes of Health guidelines and approved by the Institutional Animal Care and Use Committee of Yonsei University Health System (permit no. 2017-0148).
Rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and placed in a stereotaxic frame. Stainless steel guide cannulae (28-gauge) were bilaterally implanted into the ACC (AP 1.5 mm from bregma, ML ± 0.6 mm from midline, DV 1.5 mm beneath the surface of the skull). The cannulae were attached to the bone with stainless steel screws and acrylic cement. Dummy cannulae were inserted into the guide cannulae to avert clogging. Rats were allowed to recover for 7 days after cannula implantation.
A model of neuropathic pain was induced by ligation and cutting of the sciatic nerve branches . Under sodium pentobarbital anesthesia, three terminal branches of the left sciatic nerve were exposed by direct incision of the skin and a section of the biceps femoris muscle. The tibial and sural nerves were tightly ligated with 4-0 black silk and cut, and the common peroneal nerve was left intact (nerve-injured; NP group). Surgical procedures for the sham-operated group were identical to those for the NP group except that the nerves were not injured. The neuropathic surgery and cannula implantation were all performed on the same day.
Mechanical Allodynia Test
Rats were individually placed in small cages with a metal mesh floor and habituated for 15 min before the test. Mechanical allodynia was measured by assessing thresholds for each hind paw withdrawal from stimulation by an electronic von Frey filament (UGO Basile, Varese, Italy). A single, un-bending filament was vertically applied to the hind paw, and licking or rapid withdrawal of the hind paw was considered a positive response. Responses were measured seven times in 2–3-min intervals. The mechanical allodynia test was performed before nerve injury and on postoperative days (PODs) 1, 4, 7, and 14 by a researcher blinded to experimental conditions.
Rapamycin Microinjection into the ACC
Rapamycin (R-5000; LC Laboratories, Woburn, MA, USA) was prepared in 0.06% dimethyl sulfoxide diluted in saline. Microinjections were performed on POD 7. Rapamycin (0.5 μl of 150, 300, and 600 nM per side over 1 min) or an equivalent amount of vehicle solution was microinjected into the ACC bilaterally via the injection cannulae, which were lowered 1 mm deeper into the ACC than the guide cannulae. The microinjection apparatus consisted of Hamilton syringes (1 μl) connected to the injection cannulae with PE-10 tubing. After injection, the injection cannulae were maintained in place for at least 1 min to allow for drug absorption into the brain and to minimize reflux along the track of the cannulae. Additional mechanical allodynia tests for confirming the effect of drug administration were performed before and 0.5, 1, 2, 4, 8, 12, and 24 h after rapamycin or vehicle solution microinjection into the ACC by a researcher blinded to microinjection substance.
Western Blot Analysis/Tissue Collection and Immunoblotting
Two hours after microinjection of rapamycin or vehicle solution on POD 7, rats were anesthetized with isoflurane and decapitated for ACC tissue sample collection. The ACC (AP + 2.2 to − 1.2 from bregma) was dissected on ice using a rat brain matrix (RWD Life Science, Shenzhen, China). Three coronal brain slices (1 mm thick) containing the ACC were dissected using a surgical blade and rapidly frozen in liquid nitrogen. For protein extraction, samples were homogenized in lysis buffer (ProPrep; Intron Biotechnology, Pyeongtaek, Korea) containing phosphatase inhibitors (Phosstop; Roche, Mannheim, Germany) and incubated on ice for 2 h. Samples were then centrifuged at 15,000 rpm for 15 min at 4 °C, and supernatants were collected. Total protein concentrations were assessed with a spectrophotometer (Nano Drop ND-1000; NanoDrop Technologies Inc., Wilmington, DE, USA), and equal amounts of protein (30 mg per well) were denatured and loaded on 10% SDS-PAGE (for mTOR, p-mTOR, p70S6K, and p-p70S6K) and 15% SDS-PAGE (for 4E-BP1 and p-4E-BP1) (Bio-Rad, Hercules, CA, USA). Proteins were transferred onto a polyvinylidene difluoride membrane (Merck Millipore, Darmstadt, Germany). Phospho-proteins were immunodetected first followed by the corresponding total protein after the blot was stripped. For enhanced visualization and analysis of 4E-BP1 and p-4E-BP1, transferred proteins were fixed to the membrane by 0.05% glutaraldehyde in TBS-0.05% Tween-20 (TBST) for 15 min at room temperature . Membranes were stained with Ponceau S (Sigma-Aldrich, St. Louis, MO, USA), and staining of the wells was visually compared. Membranes were blocked by incubation in 5% bovine serum albumin in TBST for 1 h at room temperature and incubation overnight at 4 °C with primary antibodies diluted in 5% bovine serum albumin in TBST. The following primary antibodies were used: mTOR (no. 2972, 1:1000; Cell Signaling Technology, Beverly, MA, USA), p-mTOR (Ser 2448, no. 2971, 1:500; Cell Signaling Technology), p70S6K (no. 2708, 1:1000; Cell Signaling Technology), p-p70S6K (Thr 389, no. 9205, 1:500; Cell Signaling Technology), 4E-BP1 (no. 9644, 1:1000; Cell Signaling Technology), p-4E-BP1 (Thr37/46, no. 2855, 1:500; Cell Signaling Technology), and β-actin (no. 3700, 1:15,000; Cell Signaling Technology). The next day, blots were washed three times in TBST and incubated with the appropriate anti-rabbit horseradish peroxidase-conjugated secondary antibody (no. 7074, 1:10,000; Cell Signaling Technology). Immunoreactive proteins were visualized by applying a chemiluminescent (ECL) detection reagent (GE Healthcare, Little Chalfont, UK) and observed using an LAS system (LAS 4000, GE Healthcare, Fuji Film Inc., Tokyo, Japan). Phospho-protein and total protein immunoreactivity was scanned and quantified using Multi-gage software (Fuji Film Inc., Tokyo, Japan). Each value was normalized to the respective β-actin band, and optical density was divided by that of the corresponding total protein band to yield a phospho-protein/total protein ratio.
On POD 7, rats were deeply anesthetized with urethane (1.25 g/kg, i.p.) immediately after mechanical allodynia testing following microinjection of rapamycin or vehicle solution into the ACC and perfused transcardially with normal saline (0.9% NaCl) via the ascending aorta followed by a 4% solution of formaldehyde in 0.1 M sodium phosphate buffer (pH 7.4). Brains were removed, post-fixed in the same paraformaldehyde solution for 4 h at 4 °C, and immersed in a 10 to 30% (w/v) sucrose gradient in phosphate-buffered saline (PBS; pH 7.4) for 24–48 h at 4 °C for cryoprotection. After cryoprotection, brains were embedded in optimal cutting temperature compound (Sakura Finetek USA Inc., Torrance, CA, USA) and cut on a cryostat (Microm HM525; Thermo Scientific, Waltham, MA, USA) into 20-μm-thick coronal sections. Double immunofluorescence staining for PSD-95/AMPAR GluA1 subunits or PSD-95/NMDAR NR2B subunits was performed. Sections containing the ACC were blocked in PBS containing 0.3% Triton X-100 (PBST) and 5% normal donkey serum for 2 h at room temperature. For double immunofluorescence, sections were incubated overnight with a mixture of mouse anti-PSD-95 (1:500, ab2723, Abcam, Cambridge, UK) and rabbit AMPA GluA1 (1:500, ab31232, Abcam) or rabbit anti-NMDAR2B (1:500, ab65783, Abcam) antibodies in PBST containing 5% normal donkey serum at 4 °C. All sections were rinsed with PBST (5 min, three times) after each step. After rinsing, sections were incubated with Cy3-conjugated donkey anti-mouse IgG (H + L) (1:200, 715-165-150, Jackson ImmunoResearch, West Grove, PA, USA) or Alexa Fluor 488-conjugated donkey anti-rabbit IgG (H + L) (1:200, 711–545-152, Jackson ImmunoResearch) secondary antibody for 2 h at room temperature. Sections were mounted with Vectashield containing DAPI to label nuclei (Vector Laboratories, Youngstown, OH, USA). In each experiment, sections from different groups were stained at the same time.
High-magnification fluorescent images were taken with a Zeiss LSM 700 confocal microscope (Carl Zeiss, Jena, Germany). Quantitative assessment of PSD-95 and AMPAR or NMDAR immunoreactivity was performed using the ImageJ 1.46r software program (National Institutes of Health, Bethesda, Maryland, USA). In addition, the total number of pixels of the stained area was quantified and expressed as immunodensity. These measurements were performed using two sections randomly selected from the five serial sections of the ACC from each animal. Immunodensities were averaged to obtain a single value for each rat.
Before imaging, rats were deeply anesthetized with urethane (1.25 g/kg, i.p.) on POD 7 and given atropine (5 mg/kg, i.p.) to suppress mucus secretion and dexamethasone sulfate (1 mg/kg, i.p.) to reduce swelling of the brain. Rats were then placed in a custom-made stereotaxic frame to stabilize the head during optical imaging. Lidocaine was applied to the skin, and a craniotomy was made that extended AP + 6 to − 2 mm from bregma and ML ± 4 mm from midline. The dura over the ACC was carefully removed. To expose the ACC, double closure of the superior sagittal sinus was performed using 4–0 black silk, and the superior sagittal sinus was then cut with microscissors and separated from the cortex. If slight bleeding occurred, it was easily controlled using a saline-moistened cotton compress. This surgical procedure was slightly modified from that described for a rat pinealectomy study and an electrophysiological study [37, 38]. The exposed ACC was stained using voltage-sensitive dye (di-2-ANEPEQ, 50 mg/mL in saline; Molecular Probes, Eugene, OR, USA) for 1 h and carefully rinsed with saline. Imaging was performed before and after application of 600 nM rapamycin or vehicle solution directly to the exposed cortex for 30 min. Heart rate was monitored by electrocardiography, and body temperature was maintained at 36 °C with a rectal probe and heating pad system (Homeothermic Blanket Control Unit; Harvard Apparatus, Holliston, MA, USA).
A pair of stainless steel electrodes was inserted into the left hind paws where the electronic von Frey filaments had been applied during behavioral testing. Stimulation of the hind paw was done with square pulses (width 0.1 ms, interstimulus interval 5 s, intensity 2.5 mA) using a stimulus isolation unit (World Precision Instruments, Sarasota, FL, USA). Changes in fluorescence after peripheral stimulation were measured using a high-resolution CCD camera (Brainvision Inc., Tokyo, Japan) equipped with a dichroic mirror with a 510–550-nm excitation filter and 590-nm absorption filter. A tungsten halogen lamp (150 W) was used for excitation of fluorescence. The imaging area was 6.4 × 4.8 mm2 and consisted of 184 × 124 pixels. The fluorescence intensity during each trial was detected for approximately 940 ms under an optical microscope (Leica Microsystems Ltd., Heerbrugg, Switzerland) equipped with a ×1 objective and ×1 projection lens. Optical signals were acquired at a rate of 3.7 ms/frame, and averages of 20 trials were recorded by an optical imaging recording system (MiCAM02; Brainvision Inc.). Optical imaging acquisition was triggered by electrocardiogram signals using a stimulus/non-stimulus subtraction method. After optical imaging, rats were euthanized by an overdose of urethane. To normalize the value of each pixel, the ratio of the intensity of fluorescence (ΔF) in each pixel relative to the initial fluorescence intensity (F) was expressed as a fractional change (ΔF/F). Amplitudes and excitatory areas of optical signals were measured using a spatial filter (9 × 9 pixels) to reduce artifacts caused by vibration and brain movements. Using captured images, fractional changes in optical signals (i.e., optical intensity) and areas of activation were quantified. Changes in optical intensity in the ACC were expressed as a percentage of fractional change in fluorescence (%ΔF/F). Activated areas were analyzed using the activated pixel number divided by the total pixel number in the region of interest (AP + 2.2 to + 0.2 mm from bregma) × 100. Data were collected and analyzed with BV Analyzer software (Brainvision Inc.).
Statistical analyses were performed using SPSS 20.0 software (IBM Corporation, Armonk, NY, USA). Behavioral data were analyzed by two-way repeated measures analysis of variance (ANOVA) followed by Bonferroni’s test for post hoc comparisons. Western blotting and immunohistochemistry data were analyzed by one-way ANOVA followed by Tukey’s test for multiple comparisons. Optical imaging data were analyzed by paired t test. All values are expressed as mean ± standard error of the mean (SEM). Values of p < 0.05 were considered statistically significant.
Development of Mechanical Allodynia Induced by Nerve Injury
Nerve Injury Activates mTOR Signaling in the ACC
Microinjection of Rapamycin into the ACC Diminishes Mechanical Allodynia After Nerve Injury
Microinjection of Rapamycin into the ACC Blocks Activation of mTOR and its Downstream Effectors in the ACC After Nerve Injury
Inhibition of mTOR Suppresses Synaptic Protein Expression in the ACC After Nerve Injury
Inhibition of mTOR Reduces Excitability in the ACC Induced by Peripheral Stimulation
Optical images of responses to peripheral stimulation before and after rapamycin treatment are shown in Fig. 6c, d. Figure 6c, d shows representative images before and after vehicle treatment or 600-nM rapamycin treatment, respectively, following 2.5-mA electrical peripheral stimulation in nerve-injured rats. As we found a maximal pain-relieving effect of 600 nM rapamycin injection, we used 600 nM rapamycin to validate neural activity in the ACC. After rapamycin treatment, neuronal activity in the ACC was strikingly reduced compared with that before treatment. Peak amplitudes induced by peripheral electrical stimulation were reduced after rapamycin treatment compared with before rapamycin treatment (t5 = 5.07, p = 0.003, paired t test, Fig. 6e). Also, the area of activation was reduced after rapamycin treatment compared with before rapamycin treatment (t5 = 8.069, p < 0.001, paired t test, Fig. 6f). By contrast, peak amplitude and activated area were not significantly different before and after vehicle treatment (p = 0.838 and p = 0.443 respectively, paired t test).
Changes in synaptic plasticity in many areas of the central nervous system are involved in pain processing and chronic pain, including the spinal cord, cortical areas, and subcortical areas [10, 12]. Previous studies show that changes of neural plasticity in the ACC are associated with persistent pain and fear memory in a mouse model . ACC neurons respond to nociceptive and non-nociceptive mechanical or thermal somatosensory stimuli as well as emotional aspects of pain [16, 40, 41]. In particular, nociceptive information is projected to the ACC from other pain-related regions, such as the medial thalamus, amygdala, and other pain-related area of the cortex .
Recently, mTOR has been found to control cancer, inflammatory, and neuropathic pain [24, 26, 31, 43]. These studies provide evidence that mTOR plays an important role in pain management but have mainly focused on mechanisms at the spinal level. The present study validated the role of mTOR signaling at the brain level by examining mechanical hyperalgesia and changes in the expression of activated mTOR (p-mTOR) and its downstream effectors (p-p70S6K and p-4E-BP1) in the ACC after nerve injury in an animal model of neuropathic pain. Our results suggest that the development of neuropathic pain induced by peripheral nerve injury is associated with increased activity of mTOR and its downstream effectors in the ACC. Previous studies report increased activity of mTOR and its downstream effectors in the spinal cord dorsal horn in the chronic constriction injury model , the rostral ventromedial medulla in the spared nerve injury model , and the IC in the nerve-injured model . Also, another study reports increased expression of p-mTOR and p-p70S6K in the ACC of a formalin-induced inflammatory animal model . Together with previous studies, our results demonstrate that the mTOR-dependent signaling pathway in the ACC is involved in the development of chronic pain. In addition, the expressions of activated mTOR and its downstream effectors on POD 14 were less than on POD 7. The differences in the expression levels on POD 14 and POD 7 might indicate that the mTOR signaling pathway in the ACC becomes less effective in maintaining nerve injury-induced chronic pain.
Previous electrophysiological studies show that rapamycin, an mTOR inhibitor, inhibits L-LTP in the hippocampus when delivered during LTP induction but not after LTP formation [18, 47]. Also, intrathecal injection of rapamycin reduces mechanical hyperalgesia behaviors and decreases phosphorylation of mTOR and its downstream effectors in the spinal cord dorsal horn in chronic constriction injury and spinal cord injury animal models [22, 44]. These results indicate that neuropathic pain could be regulated by rapamycin. In the present study, mechanical allodynia was significantly reduced after microinjection of rapamycin into the ACC, and levels of phosphorylation of mTOR, p70S6K, and 4E-BP1 were significantly decreased in a dose-dependent manner. In particular, 600 nM rapamycin was the most effective dosage for reducing mechanical allodynia and phosphorylation of mTOR, p70S6K, and 4E-BP1. Previous studies have reported that rapamycin decreases pain behaviors in a dose-dependent manner without a change in locomotor activity and apparent adverse effects [48, 49, 50]. Thus, these results suggest that rapamycin reduces pain-related behaviors by inhibiting the activation of mTOR.
mTOR regulates synaptic protein transcription via many factors . Activation of mTOR regulates the phosphorylation of downstream effectors such as p70S6K and 4E-BP1, which in turn regulate mRNA translation and protein synthesis [27, 52] and thereby affect protein translation . Local protein synthesis in axons and dendrites contributes to regulating long-lasting synaptic plasticity, neurite development, and response to nerve injury [53, 54]. It is well-known that mTOR regulates local transcription of mRNA through phosphorylation of p70S6K and 4E-BP1 . Phosphorylation of p70S6K mediates translation initiation and polypeptide extension, whereas phosphorylation of 4E-BP1 reduces cap-dependent transcription by inhibiting eukaryotic initiation factor 4E (eIF4E) . Activation of mTOR signaling induces dendritic protein synthesis, including the synthesis of postsynaptic glutamate receptors and postsynaptic density proteins necessary for maintaining long-lasting forms of synaptic plasticity, especially L-LTP [52, 55]. A previous study has shown that intrathecally administered rapamycin reduces expression levels of activated mTOR and its downstream effectors in the spinal dorsal horn at 7 days, but not 14 days, after nerve injury . This finding agrees well with our observations showing that expression levels of p-mTOR in the ACC increased on 7 days after nerve injury and declined thereafter. We have also observed that inhibition of mTOR signaling by rapamycin injected bilaterally into the ACC on POD 7 reduced nerve injury-induced pain behavior. Thus, it is suggested that during the development of chronic pain, activation of mTOR signaling is necessary to express pain behaviors. In addition, activation of postsynaptic receptors affects the development of chronic hyperalgesia to noxious stimuli . Post-synaptic density (PSD), which binds to postsynaptic receptors and adhesion molecules, is maintained by an abundant set of scaffold proteins and has a role in mediating activation of synaptic receptors for biochemical signaling events in post-synaptic neurons . In particular, the interaction between the NMDA receptor NR2B subunit and PSD-95 plays an important role in synaptic plasticity in the central nervous system underlying the development of neuropathic pain after peripheral nerve injury . The AMPA receptor GluA1 subunit also contributes to pain-related LTP expression in the ACC . Thus, it is possible that the mTOR pathway induces long-term changes in synaptic efficacy by facilitating interaction of glutamate receptors with PSD proteins, leading to the long-lasting synaptic plasticity associated with chronic pain.
Here, we provide strong evidence that mTOR contributes to neuropathic pain induced by peripheral nerve injury by increasing the excitability of pyramidal neuron in the ACC. Our immunofluorescence staining showed that the expression of PSD-95 was increased at apical dendrites of ACC pyramidal neurons after nerve injury and confirmed increased interactions between PSD-95 and glutamate receptors (AMPAR GluA1 and NMDAR NR2B subunits). In addition, rapamycin administration into the ACC decreased the expression of and interaction between these synaptic proteins. These results demonstrate that rapamycin suppresses the activity of mTOR and its downstream effectors, thereby decreasing translation and synthesis of mTOR-mediated synaptic proteins. Because both the ACC and primary somatosensory cortex, which are located in the pain ascending pathway, receive nociceptive inputs from the medial thalamus, the increased activity of pyramidal cells in both areas reflects their participation in a cerebral cortical circuit involved in chronic pain. In fact, electrophysiological studies show the activation of many pyramidal neurons of ACC layer II/III after nerve injury [59, 60], and some studies show that inhibiting the hyperactivity or plasticity of pyramidal neurons in the ACC lessens the development of chronic pain [59, 61]. Combining our current results with those of previous studies, we speculated that rapamycin modulates the interaction between GluA1-PSD-95 and NR2B-PSD-95 by regulating the mTOR signaling pathway that controls synaptic plasticity in the ACC. In other words, mTOR signaling in the ACC is an important component in neuropathic pain induced by nerve damage.
We performed optical imaging using voltage-sensitive dye as an additional means to verify neuronal activation of the ACC in neuropathic pain and to demonstrate changes in neuronal activity after rapamycin treatment. This electrophysiological technique allows the recording of membrane potential changes to provide visual confirmation of the activity of the neuronal population . We delivered electrical stimuli to hind paws to observe changes in nerve activity after rapamycin treatment in the ACC of an animal nerve injury model. Our results indicate that the ACC of neuropathic rats was extensively activated in response to peripheral electrical stimulation, and this ACC activation was diminished by rapamycin. In other words, excitability in the ACC after nerve injury decreased after treatment with an mTOR inhibitor. Previous studies report similar results in the IC, which is also involved in pain processing . These findings, together with those of previous studies, indicate that rapamycin could reduce the response to peripheral stimulation before the development of LTP. The purpose of this study was to validate the efficacy of inhibiting mTOR activation in the ACC in relieving neuropathic pain caused by nerve injury. Consistent with previous studies, our findings suggest that protein synthesis, which maintains a chronic pain state, is suppressed by inhibiting the activity of mTOR prior to LTP development. However, the effect of pain relief did not persist more than 24 h after rapamycin microinjection; therefore, future studies investigating the maintenance of this effect are needed. In conclusion, the present study suggests that the mTOR pathway in the ACC is an important avenue for controlling neuropathic pain produced by peripheral nerve damage and provides evidence for a vital role of synaptic plasticity in the ACC in the processing of pain.
This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT; Ministry of Science and ICT) (NRF-2017R1A2B3005753) and by The Chung Yang, Cha Young Sun & Jang Hi Joo Memorial Fund.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 17.Qu C, King T, Okun A, Lai J, Fields HL, Porreca F (2011) Lesion of the rostral anterior cingulate cortex eliminates the aversiveness of spontaneous neuropathic pain following partial or complete axotomy. Pain 152(7):1641–1648. https://doi.org/10.1016/j.pain.2011.03.002 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Cammalleri M, Lutjens R, Berton F et al (2003) Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1. Proc Natl Acad Sci U S A 100(24):14368–14373. https://doi.org/10.1073/pnas.2336098100 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Takei N, Inamura N, Kawamura M et al (2004) Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites. J Neurosci 24(44):9760–9769. https://doi.org/10.1523/jneurosci.1427-04.2004 CrossRefPubMedGoogle Scholar
- 24.Norsted Gregory E, Codeluppi S, Gregory JA, Steinauer J, Svensson CI (2010) Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation. Neuroscience 169(3):1392–1402. https://doi.org/10.1016/j.neuroscience.2010.05.067 CrossRefPubMedGoogle Scholar
- 28.Alamo JM, Barrera L, Casado MD et al (2009) Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. Transplant Proc 41(6):2181–2183. https://doi.org/10.1016/j.transproceed.2009.06.083 CrossRefPubMedGoogle Scholar
- 41.Koga K, Li X, Chen T, Steenland HW, Descalzi G, Zhuo M (2010) In vivo whole-cell patch-clamp recording of sensory synaptic responses of cingulate pyramidal neurons to noxious mechanical stimuli in adult mice. Mol Pain 6:62. https://doi.org/10.1186/1744-8069-6-62 CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Wang J, Feng DY, Li ZH et al (2015) Activation of the mammalian target of rapamycin in the rostral ventromedial medulla contributes to the maintenance of nerve injury-induced neuropathic pain in rat. Neural Plast 2015:394820. https://doi.org/10.1155/2015/394820 CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Shih MH, Kao SC, Wang W, Yaster M, Tao YX (2012) Spinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats. J Pain 13(4):338–349. https://doi.org/10.1016/j.jpain.2011.12.006 CrossRefPubMedPubMedCentralGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.